Currently Viewing:
Currently Reading
AJMC® in the Press, September 6, 2019
September 06, 2019 – AJMC Staff
Top 5 AJMC® Articles of August 2019
August 31, 2019
What We're Reading: Duplicate Medicare Payments; Long-Term Antidepressant Use Worries; Nebraska Medicaid Expansion
August 29, 2019 – AJMC Staff
AJMC® Research Roundup: August 2019
August 29, 2019
AJMC® in the Press, August 23, 2019
August 23, 2019 – AJMC Staff
AJMC® in the Press, August 16, 2019
August 16, 2019 – AJMC Staff
5 Findings From the August 2019 Issue of AJMC®
August 16, 2019 – Christina Mattina
What We're Reading: Medicare Observation Rules on Trial; California Charity Care; AAP Statement on Racism
August 12, 2019 – AJMC Staff
This Week in Managed Care: August 9, 2019
August 09, 2019

AJMC® in the Press, September 6, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Health Payer Intelligence referenced a study in this month’s issue of The American Journal of Managed Care® (AJMC®) in its article on Medicare Advantage payment cuts. The study, “Did Medicare Advantage Payment Cuts Affect Beneficiary Access and Affordability?,” found that the payment cuts, issued under the Affordable Care Act, were not significantly associated with healthcare access or affordability.

A study published in the August issue of AJMC® looked at the impact of delays in treatment with chimeric antigen receptor (CAR) T-cell therapy and found that delays limit the social value generated by the treatment for acute lymphoblastic leukemia and diffuse large B-cell lymphoma. The study, “The Potential Impact of CAR T-Cell Treatment Delays on Society,” was highlighted in an article from Cancer Network.

Three articles from AJMC®’s sister site The Center for Biosimilars® were featured in a piece appearing in the American Medical Association Journal of Ethics regarding biosimilar use in the United States. The article “Pfizer Launches Biosimilar Filgrastim, Nivestym, at a Substantial Discount” covered Pfizer’s indication that Nivestym would be priced at a wholesale acquisition cost (WAC) of $350.40 per 480-mcg prefilled syringe, 30.3% lower than that of the reference Neupogen, and the article “Mylan to Launch Fulphila at 33% Discount to Neulasta” covered Mylan’s decision to launch its biosimilar pegfilgrastim at a WAC of $4174 per syringe, a 33% discount to the WAC of Amgen’s reference product, Neulasta. The third article, “Coherus Confirms That It Has Launched Its Pegfilgrastim Biosimilar, Udenyca,” covered the launch of Coherus BioSciences’ pegfilgrastim biosimilar, Udenyca, in the United States.

An article from Advisory Board cited the AJMC® published study “Influence of Out-of-Network Payment Standards on Insurer–Provider Bargaining: California’s Experience,” which concluded that the state’s experience implementing a policy to address surprise medical billing shows that out-of-network payment standards can influence payer–provider bargaining leverage, affecting prices and network breadth. However, the article also included the contributor piece “Can We Stop Surprise Medical Bills AND Strengthen Provider Networks? California Did,” written for, the website of AJMC®, by America’s Health Insurance Plans that argued that in-network specialty doctors in the state have increased since the legislation passed.

Sputnik News referred to an article on covering the impact of soda consumption on mortality risk. The article, “Large European Study Links Soda Consumption to Greater Risk of Mortality, Including From Parkinson,” reported on findings from a population-based study from 10 European countries that found those who drank 2 or more glasses of soda per day had a higher risk of death than those who drank less than 1 glass per month.

The 2012 AJMC® published study “Personalized Preventive Care Leads to Significant Reductions in Hospital Utilization” was featured in an article appearing in Daily Breeze. The study concluded that the MDVIP model of personalized preventive care allows the physician to take a more proactive, rather than reactive, approach to care.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up